Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02402595 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02402595 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 24 participants.
The verdict
NCT02402595, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of a potent CYP3A4 inhibitor, itraconazole, on the steady-state PK of AVP-923 and AVP-786.
Interventions
- DRUG Itraconazole
- DRUG AVP-923
- DRUG AVP-786
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-03-01 |
| Est. Completion | 2015-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02402595
The ClinicalTrials.gov registry entry for NCT02402595 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itraconazole is the first listed.
NCT02402595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02402595 about?
NCT02402595 is a clinical study titled "Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts". The purpose of this study is to determine the effects of a potent CYP3A4 inhibitor, itraconazole, on the steady-state PK of AVP-923 and AVP-786.
What is the current status of trial NCT02402595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-03-01. Estimated completion is 2015-07-01.
What interventions are being tested in trial NCT02402595?
The interventions under investigation include: Itraconazole (DRUG), AVP-923 (DRUG), AVP-786 (DRUG).
Who is sponsoring clinical trial NCT02402595?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.